Core Viewpoint - Sight Sciences, Inc. has launched the OMNI Edge Surgical System, enhancing its OMNI product family with advanced features for minimally invasive glaucoma surgery (MIGS) [1][2][5] Product Features - OMNI Edge incorporates TruSync™ technology, which synchronizes viscoelastic delivery with the surgeon's control, allowing for consistent deployment along Schlemm's canal [2][13] - The system features an expanded viscoelastic capacity of 21 µL, nearly double the previous 11 µL capacity of the OMNI Surgical System, while maintaining safety and usability [2][13] - OMNI Edge is designed to treat all three areas of resistance in the aqueous outflow system, making it versatile for various stages of primary open-angle glaucoma (POAG) [2][7] Clinical Insights - Early clinical use of OMNI Edge has been positively received, with enhancements in ergonomics and predictability noted by practitioners [3] - The OMNI procedure has demonstrated safety, effectiveness, and durability in over 300,000 procedures, establishing its leadership in canal-based MIGS [4] Market Position - The introduction of OMNI Edge allows surgeons to choose between OMNI and OMNI Edge technologies, catering to diverse surgical preferences and patient needs [5] - OMNI Edge is currently available only in the United States, indicating a focused market strategy [5] Company Commitment - Sight Sciences emphasizes its dedication to innovation in glaucoma care through ongoing collaboration with the ophthalmic community [4]

MENLO PARK, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced plans to present at the 24th Annual Needham Healthcare Conference being held virtually. Sight Sciences’ management is scheduled to present on Tuesday, April 8, 2025, at 12:45 pm PT / 3:45 pm ET. Inter ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40587 SIGHT SCIENCES, INC. (Exact name of Registrant as specified in its Charter) Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware 80-0625749 (State or other jurisdiction of ...

Financial Data and Key Metrics Changes - In Q4 2024, the company generated total revenue of $19.1 million, reflecting a 2% increase compared to the same period in the prior year [10][36] - Surgical glaucoma revenue for Q4 2024 was $18.8 million, up 9% year-over-year, driven by a 7% increase in ordering accounts and a 6% increase in account utilization [37][16] - Dry eye revenue for Q4 2024 was $0.3 million, a decrease from $1.6 million in the same period last year, primarily due to fewer SmartLid sales [38][36] - Gross margin for Q4 was 87%, an increase from 85% in the prior year, mainly due to an improved surgical glaucoma product mix [39] - The net loss for Q4 was $11.8 million, or $0.23 per share, compared to a net loss of $10.7 million, or $0.22 per share for Q4 2023 [39] Business Line Data and Key Metrics Changes - Surgical glaucoma revenue grew 9% year-over-year, despite headwinds from new Medicare LCDs affecting multiple MIGS procedures [16][37] - The company experienced increased surgical glaucoma ordering accounts and revenue, both sequentially and year-over-year [12] - Dry eye segment focused on achieving reimbursed market access, with a significant decline in revenue due to strategic shifts [36][24] Market Data and Key Metrics Changes - The company estimates over 13 million U.S. patients diagnosed with Meibomian gland disease, indicating a significant market opportunity for TearCare [25] - The MIGS market has faced challenges due to new Medicare LCDs, which restrict multiple MIGS procedures during cataract surgery [17][19] - Despite short-term declines in MIGS device utilization, the company anticipates long-term growth driven by increasing patient demand for glaucoma treatment [19] Company Strategy and Development Direction - The company aims to build commercial momentum in MIGS through customer education and engagement, and establish equitable reimbursement for TearCare [13][14] - The introduction of OMNI Edge is planned for the first half of 2025, designed to meet varying physician preferences and patient needs [22][21] - The long-term strategy focuses on pioneering the interventional treatment market for moderate to severe MGD, with a goal to unlock a multi-billion-dollar market opportunity [26][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow break-even without raising additional equity capital [35] - The company expects 2025 to be transformational, anticipating initial positive coverage and payment decisions for TearCare [14][41] - Management acknowledged the impact of a 20% tariff on goods from China, which may affect gross margins and operational results in 2025 [44][43] Other Important Information - The company ended Q4 with $120.4 million in cash and cash equivalents, and $40 million in debt [40] - The company has not yet received monetary damages from a patent infringement case against Alcon, with the final ruling still pending [41] Q&A Session Summary Question: How is market development on the standalone MIGS market going? - Management noted good momentum in capturing broader adoption of interventional mindset in glaucoma care, with ongoing education efforts [48][51] Question: Can you provide updates on TearCare reimbursement claims? - Management indicated an increasing volume of claims and early traction with specific payers, but noted that claims are still being processed individually [58][61] Question: What are the trends in surgical glaucoma since the new LCDs? - Management reported that trends are tracking as expected, with good engagement across the community regarding OMNI's role in treatment [66][70] Question: How is the competitive landscape affecting OMNI volumes? - Management expressed confidence in OMNI's strong position as a pioneer in the category, despite new entrants and potential trialing disruptions [115][117]

Group 1 - Sight Sciences, Inc. reported revenue of $19.07 million for the quarter ended December 2024, reflecting a 1.7% increase year-over-year and a surprise of +0.50% over the Zacks Consensus Estimate of $18.98 million [1] - The company's EPS for the quarter was -$0.23, slightly worse than the -$0.22 reported in the same quarter last year, resulting in a -15.00% surprise compared to the consensus EPS estimate of -$0.20 [1] - Over the past month, shares of Sight Sciences have decreased by -11.8%, while the Zacks S&P 500 composite has seen a decline of -4.1%, indicating underperformance relative to the broader market [3] Group 2 - Revenue from Dry Eye was reported at $0.30 million, slightly below the estimated $0.31 million, representing a significant year-over-year decline of -81% [4] - Revenue from Surgical Glaucoma was $18.77 million, which is lower than the average estimate of $19.08 million but shows a year-over-year increase of +9.4% [4] - Gross Profit for Dry Eye was $0.16 million, exceeding the average estimate of $0.02 million, while Gross Profit for Surgical Glaucoma was $16.41 million, slightly below the average estimate of $16.49 million [4]

Group 1 - Sight Sciences, Inc. reported a quarterly loss of $0.23 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.20, and compared to a loss of $0.22 per share a year ago, indicating an earnings surprise of -15% [1] - The company posted revenues of $19.07 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 0.50%, and showing an increase from $18.75 million in the same quarter last year [2] - Sight Sciences has surpassed consensus EPS estimates two times over the last four quarters and topped consensus revenue estimates three times during the same period [2] Group 2 - The stock has underperformed, losing about 32.1% since the beginning of the year, while the S&P 500 has declined by only -1.8% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.23 on revenues of $19.11 million, and for the current fiscal year, it is -$0.91 on revenues of $82.27 million [7] - The Zacks Industry Rank for Medical - Instruments is currently in the top 34% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Financial Results - Sight Sciences, Inc. announced preliminary unaudited financial results for Q4 and the year ended December 31, 2024[6] - The press release detailing financial results was issued on January 14, 2025[6] Company Classification - The company is classified as an emerging growth company under the Securities Act of 1933[5] Regulatory Information - The financial statements and exhibits are not deemed "filed" under the Securities Exchange Act of 1934[7] - The report was signed by Chief Financial Officer Alison Bauerlein[11]

Core Insights - Sight Sciences, Inc. reported financial results for Q4 and full year 2024, with a focus on advancing strategic initiatives for 2025 [1][4][15] Recent Financial Highlights - Q4 2024 revenue was $19.1 million, a 2% increase year-over-year, while full year 2024 revenue was $79.9 million, a 1% decrease compared to 2023 [5][10] - Surgical Glaucoma revenue for Q4 2024 was $18.8 million, up 9% year-over-year, driven by a 7% increase in ordering accounts and a 6% increase in account utilization [5][10] - Dry Eye revenue for Q4 2024 was $0.3 million, down from $1.6 million in the same period last year, attributed to fewer SmartLids sales [5][10] - Gross profit for Q4 2024 was $16.6 million, with a gross margin of 87%, compared to 85% in the prior year [6][11] - Full year 2024 operating expenses were reduced to $118.8 million, a 6% decrease from 2023 [12] Recent Business and Clinical Highlights - The company published a 36-month analysis demonstrating the long-term effectiveness of the OMNI Surgical System for managing glaucoma, showing significant reductions in intraocular pressure [6] - A Budget Impact Analysis indicated that a 20% increase in TearCare market share could yield annual savings of approximately $36.87 per member in a hypothetical health plan with one million covered lives [6] Management Commentary - The CEO emphasized the focus on building commercial momentum in the MIGS market, establishing equitable reimbursement for TearCare, and advancing clinical data to support technology adoption [4] - The company anticipates that the OMNI procedure will remain a leading choice for glaucoma treatment despite market fluctuations [4] 2025 Financial Guidance - Revenue for 2025 is expected to range from $70.0 million to $75.0 million, reflecting a 6% to 12% decline compared to 2024, influenced by new Medicare LCDs affecting MIGS procedures [15] - Adjusted operating expenses for 2025 are projected to be between $105.0 million and $107.0 million, representing a 4% to 6% increase compared to 2024 [16]

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Sight Sciences, Inc. due to higher revenues, with a focus on how actual results will compare to estimates impacting stock price [1][2] Earnings Expectations - The earnings report is expected on March 5, 2025, with a consensus estimate of a quarterly loss of $0.20 per share, reflecting a year-over-year change of +9.1% [3] - Revenues are projected to be $18.98 million, which is an increase of 1.2% from the previous year [3] Estimate Revisions - The consensus EPS estimate has been revised down by 4.49% over the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Sight Sciences is lower than the Zacks Consensus Estimate, leading to an Earnings ESP of -15% [10][11] Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from consensus estimates, with positive readings being more predictive of earnings beats [6][7] - Stocks with a positive Earnings ESP and a Zacks Rank of 1, 2, or 3 have shown a nearly 70% success rate in delivering positive surprises [8] Historical Performance - Sight Sciences has beaten consensus EPS estimates three out of the last four quarters, with a recent surprise of +4.35% when it reported a loss of $0.22 against an expected loss of $0.23 [12][13] Conclusion - Despite the potential for an earnings beat, other factors may influence stock movement, and Sight Sciences does not currently appear to be a strong candidate for an earnings beat [14][16]

Core Viewpoint - The OMNI Surgical System demonstrates significant long-term intraocular pressure (IOP) reduction and medication reduction in treating primary open-angle glaucoma, supported by data from a meta-analysis and the IRIS Registry [1][2][4] Group 1: Clinical Effectiveness and Safety - Presentations at the 2025 American Glaucoma Society Annual Meeting will showcase new data on the clinical effectiveness and safety of the OMNI Surgical System across diverse patient populations [1][2] - Data from the IRIS Registry indicates that OMNI, when combined with cataract surgery in Black patients, resulted in significant IOP reductions and decreased medication use over 24 to 36 months [3][4][13] - A systematic review and meta-analysis of 22 studies involving 2,379 eyes concluded that OMNI consistently reduced IOP and medication needs for up to 36 months [6][8] Group 2: Data Sources and Partnerships - The data presented is curated by Verana Health, in partnership with the American Academy of Ophthalmology IRIS Registry, which is one of the largest clinical data registries in medicine [2][4][16] - The IRIS Registry has collected over 851 million patient encounters and 80 million unique de-identified patients from more than 30 electronic health records and 15,000 eye care professionals across the U.S. [4] Group 3: Company Commitment and Future Directions - Sight Sciences emphasizes its commitment to advancing glaucoma care by providing effective treatment options that reduce medication dependence and improve patient quality of life [4][11] - The company aims to transform eye care through innovative interventional technologies, with the OMNI Surgical System being a key product indicated for reducing IOP in adult patients with primary open-angle glaucoma [11][15]